Table 1.
Baseline study characteristics of 143 muscle-invasive bladder cancer patients treated with (chemo)radiation of the bladder and who were under surveillance with urinary molecular diagnostics
| Characteristic | Characteristic | ||
|---|---|---|---|
| Age at diagnosis (yr) | Chemotherapy, n (%) | ||
| Median (IQR) | 76 (68–81) | Yes | 54 (38) |
| Sex, n (%) | Treatment, n (%) | ||
| Male | 115 (80) | Radiotherapy + chemotherapy | 89 (62) |
| Age | Radiotherapy + PC | 15 (11) | |
| Median (IQR) | 76 (68–88) | Radiotherapy alone | 39 (27) |
| Smoking, n (%) | Reason for radiotherapy, n (%) | ||
| Yes/stopped | 113 (79) | Contraindication for RC | 83 (58) |
| Missing | 9 (6) | Opted bladder-sparing therapy | 60 (42) |
| History of NMIBC, n (%) | Time to recurrence | ||
| Yes | 27 (19) | Median (IQR) | 16 (12–26) |
| Clinical T stage, n (%) | Patients with progression a,n (%) | ||
| cT2 | 112 (78) | Yes | 35 (24) |
| cT3 | 30 (21) | Time to progression | |
| cT4 | 1 (1) | Median (IQR) | 18 (12–26) |
| Tumor grade (1973), n (%) | Death, n (%) | ||
| G2 | 15 (11) | No | 85 (59) |
| G3 | 122 (85) | Yes (any cause) | 54 (38) |
| Non-UCC | 6 (4) | Yes (bladder cancer) | 23 (16) |
| Concomitant carcinoma in situ, n (%) | Missing | 4 (3) | |
| Yes | 45 (32) | Lost to follow-up, n (%) | |
| Variant histology, n (%) | Yes | 30 (21) | |
| Yes | 36 (25) | Study follow-up (mo) b | |
| Hydronephrosis at diagnosis, n (%) | Median (IQR) | 20 (10–33) | |
| Yes | 18 (13) | Treatment follow-up (mo) c | |
| Missing | 5 (3) | Median (IQR) | 30 (19–49) |
| Prior intravesical treatment, n (%) | |||
| Yes, chemotherapy | 6 (4) | ||
| Yes, BCG | 16 (11) |
BCG = bacillus Calmette-Guérin; CT = computed tomography; IQR = interquartile range; NMIBC = non–muscle-invasive bladder cancer; PC = partial cystectomy; RC = radical cystectomy. Please note: for variables with a positive or negative outcome, only the positive outcome is reported due to table size limitations.
a
Progression was defined as the development of recurring biopsy-proven ≥T2 tumor, lymph node, and/or metastatic disease (using CT-scan imaging).
b
Time between study inclusion and last contact.
c
Time between start of radiotherapy and last contact.